Capricor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 04:05 pm EST
Share
Capricor Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 6.19 million compared to USD 1.59 million a year ago. Revenue was USD 6.19 million compared to USD 1.59 million a year ago. Net loss was USD 6.39 million compared to USD 6.37 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.26 a year ago.
For the nine months, sales was USD 13.09 million compared to USD 1.59 million a year ago. Revenue was USD 13.09 million compared to USD 1.59 million a year ago. Net loss was USD 21.53 million compared to USD 21.3 million a year ago. Basic loss per share from continuing operations was USD 0.85 compared to USD 0.87 a year ago.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.